Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bianchi VE, Herrera PF, Laura R. Effect of nutrition on neurodegenerative diseases. A systematic review. Nutr. Neurosci. 24(10), 810–834 (2021).
  Medline CASGoogle Scholar
• 2. Vaquer-Alicea J, Diamond MI. Propagation of protein aggregation in neurodegenerative diseases. Annu. Rev. Biochem. 88, 785–810 (2019).
  Medline CASGoogle Scholar
• 3. Vallerga CL, Zhang F, Fowdar J et al. Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson's disease. Nat. Commun. 11(1), 1238 (2020).
  Medline CASGoogle Scholar
• 4. Xu Y, Xu L, Han M et al. Altered mitochondrial DNA methylation and mitochondrial DNA copy number in an APP/PS1 transgenic mouse model of Alzheimer disease. Biochem. Biophys. Res. Commun. 520(1), 41–46 (2019).
  Medline CASGoogle Scholar
• 5. Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P et al. Alzheimer's disease: an updated overview of its genetics. Int. J. Mol. Sci. 24(4), 3754 (2023).
  Medline CASGoogle Scholar
• 6. Nalls MA, Blauwendraat C, Vallerga CL et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18(12), 1091–1102 (2019).
  Medline CASGoogle Scholar
• 7. Zhou L-T, Liu D, Kang H-C et al. Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease. Sci. Adv. 9(16), eabq7105 (2023).
  Medline CASGoogle Scholar
• 8. Zhang D, Zhang J, Wang Y et al. Targeting epigenetic modifications in Parkinson's disease therapy. Med. Res. Rev. 43, 1748–1777 (2023).
  Medline CASGoogle Scholar
• 9. Shen L, Wang C, Chen L, Wong G. Dysregulation of MicroRNAs and PIWI-Interacting RNAs in a Caenorhabditis elegans Parkinson's disease model overexpressing human α-synuclein and influence of tdp-1. Front. Neurosci. 15, 600462 (2021).
  MedlineGoogle Scholar
• 10. Cammann D, Lu Y, Cummings MJ et al. Genetic correlations between Alzheimer's disease and gut microbiome genera. Sci. Rep. 13(1), 5258 (2023).
  Medline CASGoogle Scholar
• 11. Morais LH, Schreiber Iv HL, Mazmanian SK. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 19(4), 241–255 (2021). •• Underlines microbiota–host interactions and the mechanisms implicating the gut microbiome in brain disorders via secretion of toxins, or health by short-chain fatty acids production, which regulates gut and blood–brain barrier permeability and numerous immune functions.
  Medline CASGoogle Scholar
• 12. Zhu B, Wang X, Li L. Human gut microbiome: the second genome of human body. Protein Cell. 1(8), 718–725 (2010).
  MedlineGoogle Scholar
• 13. Zhao Y, Jaber V, Lukiw WJ. Gastrointestinal tract microbiome-derived pro-inflammatory neurotoxins in Alzheimer's disease. J. Aging Sci. 9(Suppl. 5), 2 (2021).
  Google Scholar
• 14. Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16(1), 35–56 (2019).
  Medline CASGoogle Scholar
• 15. Ghosh TS, Shanahan F, O'toole PW. The gut microbiome as a modulator of healthy ageing. Nat. Rev. Gastroenterol. Hepatol. 19(9), 565–584 (2022).
  MedlineGoogle Scholar
• 16. Stan TL, Soylu-Kucharz R, Burleigh S et al. Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease. Sci. Rep. 10(1), 18270 (2020).
  Medline CASGoogle Scholar
• 17. Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer's disease – a critical review. Mol. Neurobiol. 56, 1841–1851 (2019).
  Medline CASGoogle Scholar
• 18. Kowalski K, Mulak A. Brain–gut–microbiota axis in Alzheimer's disease. J. Neurogastroenterol. Motil. 25(1), 48 (2019).
  MedlineGoogle Scholar
• 19. Shandilya S, Kumar S, Jha NK, Kesari KK, Ruokolainen J. Interplay of gut microbiota and oxidative stress: perspective on neurodegeneration and neuroprotection. J. Adv. Res. 38, 223–244 (2022).
  Medline CASGoogle Scholar
• 20. Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb. Perspect. Med. 2(5), a006148 (2012).
  MedlineGoogle Scholar
• 21. Scheiblich H, Trombly M, Ramirez A, Heneka MT. Neuroimmune connections in aging and neurodegenerative diseases. Trends Immunol. 41(4), 300–312 (2020).
  Medline CASGoogle Scholar
• 22. Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer's disease. Annu. Rev. Food Sci. Technol. 10, 619–639 (2019).
  Medline CASGoogle Scholar
• 23. Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2), 312–339 (2019).
  Medline CASGoogle Scholar
• 24. Risacher SL, Anderson WH, Charil A et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 89(21), 2176–2186 (2017).
  MedlineGoogle Scholar
• 25. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2(5), a006270 2012).
  MedlineGoogle Scholar
• 26. Naj A, Schellenberg G, Alzheimer's Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimer's disease: an overview. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 174, 5–26 (2017).
  MedlineGoogle Scholar
• 27. Wang Z, Zhao Y, Xu N et al. NEAT1 regulates neuroglial cell mediating Aβ clearance via the epigenetic regulation of endocytosis-related genes expression. Cell. Mol. Life Sci. 76, 3005–3018 (2019). • Demonstrates that epigenetic regulatory mechanisms are important in neuroglia-mediated Aβ clearance through regulation of Aβ endocytosis-related gene expression
  Medline CASGoogle Scholar
• 28. Smith AR, Smith RG, Condliffe D et al. Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain. Neurobiol. Aging 47, 35–40 (2016).
  Medline CASGoogle Scholar
• 29. Lardenoije R, Roubroeks JA, Pishva E et al. Alzheimer's disease-associated (hydroxy) methylomic changes in the brain and blood. Clin. Epigenetics 11(1), 1–15 (2019).
  MedlineGoogle Scholar
• 30. Song H, Yang J, Yu W. Promoter hypomethylation of TGFBR3 as a risk factor of alzheimer's disease: an integrated epigenomic-transcriptomic analysis. Front. cell dev. biol. 9, 825729 (2022).
  MedlineGoogle Scholar
• 31. Lang A-L, Eulalio T, Fox E et al. Methylation differences in Alzheimer's disease neuropathologic change in the aged human brain. Acta Neuropathol. Commun. 10(1), 1–17 (2022).
  MedlineGoogle Scholar
• 32. Sommerer Y, Dobricic V, Schilling M et al. Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease. Alzheimer's Res. Ther. 15(1), 92 (2023).
  Medline CASGoogle Scholar
• 33. Park H, Shin J, Kim Y, Saito T, Saido TC, Kim J. CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer's disease. Transl. Neurodegener. 11(1), 1–12 (2022).
  MedlineGoogle Scholar
• 34. Santana DA, Smith MDaC, Chen ES. Histone modifications in alzheimer's disease. Genes 14(2), 347 (2023).
  Medline CASGoogle Scholar
• 35. Zotarelli-Filho IJ, Mogharbel BF, Irioda AC et al. State of the art of microRNAs signatures as biomarkers and therapeutic targets in Parkinson's and Alzheimer's diseases: a systematic review and meta-analysis. Biomedicines 11(4), 1113 (2023).
  Medline CASGoogle Scholar
• 36. De Bastiani MA, Bellaver B, Brum WS et al. Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies. Brain Behav. Immun. 110, 175–184 (2023).
  MedlineGoogle Scholar
• 37. Shireby G, Dempster EL, Policicchio S et al. DNA methylation signatures of Alzheimer's disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. Nat. Commun. 13(1), 5620 (2022).
  Medline CASGoogle Scholar
• 38. Kim E, Kim H, Jedrychowski MP et al. Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling. Neuron 111(22), 3619–3633.e8 (2023).
  Medline CASGoogle Scholar
• 39. Nalivaeva NN, Belyaev ND, Turner AJ. New insights into epigenetic and pharmacological regulation of amyloid-degrading enzymes. Neurochem. Res. 41, 620–630 (2016).
  Medline CASGoogle Scholar
• 40. Chen Y-A, Lu C-H, Ke C-C et al. Evaluation of class IIA histone deacetylases expression and in vivo epigenetic imaging in a transgenic mouse model of Alzheimer's disease. Int. J. Mol. Sci. 22(16), 8633 (2021).
  Medline CASGoogle Scholar
• 41. Hugais MM, Cobos SN, Bennett SA, Paredes J, Foran G, Torrente MP. Changes in histone H3 acetylation on lysine 9 accompany Aβ 1-40 overexpression in an Alzheimer's disease yeast model. MicroPubl. Biol. 2021, doi: 10.17912/micropub.biology.000492 (2021).
  Google Scholar
• 42. Blanco-Luquin I, Acha B, Urdánoz-Casado A et al. NXN gene epigenetic changes in an adult neurogenesis model of Alzheimer's disease. Cells 11(7), 1069 (2022).
  Medline CASGoogle Scholar
• 43. Zhang W, Young JI, Gomez L et al. Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. Alzheimer's Res. Ther. 15(1), 78 (2023).
  Medline CASGoogle Scholar
• 44. Shao Y, Shaw M, Todd K et al. DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease. J. Hum. Genet. 63(4), 459–471 (2018).
  Medline CASGoogle Scholar
• 45. Fertan E, Gendron WH, Wong AA, Hanson GM, Brown RE, Weaver IC. Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer's disease. Sci. Rep. 13(1), 2043 (2023).
  Medline CASGoogle Scholar
• 46. Klein H-U, Mccabe C, Gjoneska E et al. Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer's human brains. Nat. Neurosci. 22(1), 37–46 (2019).
  Medline CASGoogle Scholar
• 47. Kakoty V, Kc S, Dubey SK, Yang C-H, Marathe SA, Taliyan R. Epigenetic regulation and autophagy modulation debilitates insulin resistance associated Alzheimer's disease condition in rats. Metab. Brain Dis. 37(4), 927–944 (2022).
  Medline CASGoogle Scholar
• 48. Maggiore A, Casale AM, Toscanelli W et al. Neuroprotective effects of PARP inhibitors in drosophila models of Alzheimer's disease. Cells 11(8), 1284 (2022).
  Medline CASGoogle Scholar
• 49. Bellver-Sanchis A, Singh Choudhary B, Companys-Alemany J et al. Structure-based virtual screening and in vitro and in vivo analyses revealed potent methyltransferase G9a inhibitors as prospective anti-Alzheimer's agents. ChemMedChem 17(13), e202200002 (2022).
  Medline CASGoogle Scholar
• 50. Liu H, Chu W, Gong L, Gao X, Wang W. MicroRNA-26b is upregulated in a double transgenic mouse model of Alzheimer's disease and promotes the expression of amyloid-β by targeting insulin-like growth factor 1. Mol. Med. Rep. 13(3), 2809–2814 (2016).
  Medline CASGoogle Scholar
• 51. Xing H, Guo S, Zhang Y, Zheng Z, Wang H. Upregulation of microRNA-206 enhances lipopolysaccharide-induced inflammation and release of amyloid-β by targeting insulin-like growth factor 1 in microglia. Mol. Med. Rep. 14(2), 1357–1364 (2016).
  Medline CASGoogle Scholar
• 52. Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid β, novel targets in sporadic Alzheimer's disease. J. Neurosci. 31(41), 14820–14830 (2011).
  Medline CASGoogle Scholar
• 53. Fu L, Jiang G, Weng H, Dick GM, Chang Y, Kassab GS. Cerebrovascular miRNAs correlate with the clearance of Aβ through perivascular route in younger 3xTg-AD mice. Brain Pathol. 30(1), 92–105 (2020).
  Medline CASGoogle Scholar
• 54. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 397(10291), 2284–2303 (2021).
  Medline CASGoogle Scholar
• 55. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14(1), 38–48 (2013).
  Medline CASGoogle Scholar
• 56. Nicoletti A, Luca A, Baschi R et al. Incidence of mild cognitive impairment and dementia in Parkinson's disease: the Parkinson's disease cognitive impairment study. Front. Aging Neurosci. 11, 21 (2019).
  Medline CASGoogle Scholar
• 57. Dehay B, Bourdenx M, Gorry P et al. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 14(8), 855–866 (2015).
  Medline CASGoogle Scholar
• 58. Li J, Jin M, Wang L, Qin B, Wang K. MDS clinical diagnostic criteria for Parkinson's disease in China. J. Neurol. 264, 476–481 (2017).
  Medline CASGoogle Scholar
• 59. Pajares M, Rojo AI, Manda G, Boscá L, Cuadrado A. Inflammation in Parkinson's disease: mechanisms and therapeutic implications. Cells 9(7), 1687 (2020).
  Medline CASGoogle Scholar
• 60. Li X, Li Q, Zhang Y et al. Nickel oxide nanoparticles increase α-synuclein amyloid formation and relevant overexpression of inflammatory mediators in microglia as a marker of Parkinson's disease. Arab. J. Chem. 14(10), 103380 (2021).
  CASGoogle Scholar
• 61. Caputi V, Giron MC. Microbiome–gut–brain axis and toll-like receptors in Parkinson's disease. Int. J. Mol. Sci. 19(6), 1689 (2018).
  MedlineGoogle Scholar
• 62. Perez-Pardo P, Dodiya HB, Engen PA et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut 68(5), 829–843 (2019).
  Medline CASGoogle Scholar
• 63. Kontopoulos E, Parvin JD, Feany MB. α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15(20), 3012–3023 (2006).
  Medline CASGoogle Scholar
• 64. Outeiro TF, Kontopoulos E, Altmann SM et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837), 516–519 (2007).
  Medline CASGoogle Scholar
• 65. Dai L, Wang J, He M et al. Lovastatin alleviates α-synuclein aggregation and phosphorylation in cellular models of synucleinopathy. Front. Mol. Neurosci. 14, 682320 (2021).
  Medline CASGoogle Scholar
• 66. Mittal S, Bjørnevik K, Im DS et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science 357(6354), 891–898 (2017).
  Medline CASGoogle Scholar
• 67. Harrison IF, Smith AD, Dexter DT. Pathological histone acetylation in Parkinson's disease: neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neurosci. Lett. 666, 48–57 (2018).
  Medline CASGoogle Scholar
• 68. Musacchio T, Yin J, Kremer F et al. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease. Behav. Brain Res. 432, 113968 (2022).
  Medline CASGoogle Scholar
• 69. Toker L, Tran GT, Sundaresan J et al. Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. Mol. Neurodegener. 16(1), 1–20 (2021).
  MedlineGoogle Scholar
• 70. Fedotova EY, Iakovenko EV, Abramycheva NY, Illarioshkin SN. SNCA gene methylation in Parkinson's disease and multiple system atrophy. Epigenomes 7(1), 5 (2023).
  Medline CASGoogle Scholar
• 71. Smith AR, Richards DM, Lunnon K, Schapira AH, Migdalska-Richards A. DNA methylation of α-synuclein intron 1 is significantly decreased in the frontal cortex of Parkinson's individuals with GBA1 mutations. Int. J. Mol. Sci. 24(3), 2687 (2023).
  Medline CASGoogle Scholar
• 72. Bakhit Y, Schmitt I, Hamed A et al. Methylation of alpha-synuclein in a Sudanese cohort. Parkinsonism Relat. Disord. 101, 6–8 (2022).
  Medline CASGoogle Scholar
• 73. Henderson AR, Wang Q, Meechoovet B et al. DNA methylation and expression profiles of whole blood in Parkinson's disease. Front. Genet. 12, 640266 (2021).
  Medline CASGoogle Scholar
• 74. Wang R, Tong S, Wang M et al. CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson's disease. Front. Aging Neurosci. 15, 1122647 (2023).
  MedlineGoogle Scholar
• 75. Magalingam KB, Somanath SD, Radhakrishnan AK. A glimpse into the genome-wide DNA methylation changes in 6-hydroxydopamine-induced in vitro model of Parkinson's disease. Exp. Neurobiol. 32(3), 119 (2023).
  MedlineGoogle Scholar
• 76. Fu KA, Paul KC, Lu AT et al. DNA methylation-based surrogates of plasma proteins are associated with Parkinson's disease risk. J. Neurol. Sci. 431, 120046 (2021).
  Medline CASGoogle Scholar
• 77. Fisher DW, Tulloch J, Yu C-E, Tsuang D. A preliminary comparison of the methylome and transcriptome from the prefrontal cortex across Alzheimer's disease and Lewy body dementia. J. Alzheimers Dis. Rep. 7(1), 279–297 (2023).
  MedlineGoogle Scholar
• 78. Gordevicius J, Li P, Marshall LL et al. Epigenetic inactivation of the autophagy–lysosomal system in appendix in Parkinson's disease. Nat. Commun. 12(1), 5134 (2021).
  Medline CASGoogle Scholar
• 79. Caldi Gomes L, Roser AE, Jain G et al. MicroRNAs from extracellular vesicles as a signature for Parkinson's disease. Clin. Transl. Med. 11(4), e357 (2021).
  MedlineGoogle Scholar
• 80. Cappelletti C, Henriksen SP, Geut H et al. Transcriptomic profiling of Parkinson's disease brains reveals disease stage specific expression changes. Acta Neuropathol. 146, 227–244 (2023).
  Medline CASGoogle Scholar
• 81. Duan Y, Wang Y, Liu Y et al. Circular RNAs in Parkinson's disease: reliable biological markers and targets for rehabilitation. Mol. Neurobiol. 60(6), 3261–3276 (2023).
  Medline CASGoogle Scholar
• 82. Meng J, Wang F, Ji L et al. Comprehensive methylation profile of CSF cfDNA revealed pathogenesis and diagnostic markers for early-onset Parkinson's disease. Epigenomics 13(20), 1637–1651 (2021).
  CASGoogle Scholar
• 83. Guhathakurta S, Kim J, Adams L et al. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson's disease. EMBO Mol. Med. 13(2), e12188 (2021).
  Medline CASGoogle Scholar
• 84. Sardoiwala MN, Srivastava AK, Kaundal B, Karmakar S, Choudhury SR. Recuperative effect of metformin loaded polydopamine nanoformulation promoting EZH2 mediated proteasomal degradation of phospho-α-synuclein in Parkinson's disease model. Nanomedicine 24, 102088 (2020).
  Medline CASGoogle Scholar
• 85. Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J. Neurosci. 30(18), 6355–6359 (2010).
  Medline CASGoogle Scholar
• 86. Srivastava AK, Choudhury SR, Karmakar S. Neuronal BMI-1 is critical for melatonin induced ubiquitination and proteasomal degradation of α-synuclein in experimental Parkinson's disease models. Neuropharmacology 194, 108372 (2021).
  Medline CASGoogle Scholar
• 87. Liu P, Sun L, Zhao X-L, Zhang P, Zhao X-M, Zhang J. PAR2-mediated epigenetic upregulation of α-synuclein contributes to the pathogenesis of Parkinson's disease. Brain Res. 1565, 82–89 (2014).
  Medline CASGoogle Scholar
• 88. Li B, Jiang Y, Xu Y, Li Y, Li B. Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor/α-synuclein axis in atrazine-induced Parkinson's disease by peripheral blood and brain microRNA profiling. Chemosphere 233, 542–548 (2019).
  Medline CASGoogle Scholar
• 89. Xylaki M, Paiva I, Al-Azzani M et al. miR-101a-3p impairs synaptic plasticity and contributes to synucleinopathy. J. Parkinsons Dis. 13, 179–196 (2023).
  Medline CASGoogle Scholar
• 90. Lin D, Zhang H, Zhang J et al. α-Synuclein induces neuroinflammation injury through the IL6ST-AS/STAT3/HIF-1α axis. Int. J. Mol. Sci. 24(2), 1436 (2023).
  Medline CASGoogle Scholar
• 91. Schaffner SL, Wassouf Z, Hentrich T, Nuesch-Germano M, Kobor MS, Schulze-Hentrich JM. Distinct impacts of alpha-synuclein overexpression on the hippocampal epigenome of mice in standard and enriched environments. Neurobiol. Dis. 186, 106274 (2023).
  Medline CASGoogle Scholar
• 92. Zhao A, Li Y, Niu M et al. SNCA hypomethylation in rapid eye movement sleep behavior disorder is a potential biomarker for Parkinson's disease. J. Parkinsons Dis. 10(3), 1023–1031 (2020).
  Medline CASGoogle Scholar
• 93. Kaut O, Kuchelmeister K, Moehl C, Wüllner U. 5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinson's disease. J. Chem. Neuroanat. 96, 41–48 (2019).
  Medline CASGoogle Scholar
• 94. Zhou T, Lin D, Chen Y et al. α-synuclein accumulation in SH-SY5Y cell impairs autophagy in microglia by exosomes overloading miR-19a-3p. Epigenomics 11(15), 1661–1677 (2019).
  CASGoogle Scholar
• 95. Tao H, Liu Y, Hou Y. miRNA-384-5p regulates the progression of Parkinson's disease by targeting SIRT1 in mice and SH-SY5Y cell. Int. J. Mol. Med. 45(2), 441–450 (2020).
  Medline CASGoogle Scholar
• 96. Obrenovich ME. Leaky gut, leaky brain? Microorganisms 6(4), 107 (2018). •• Explores the importance of leaky gut and microbiota dysbiosis in altering blood–brain barrier permeability and increasing the risk of neurological disorders such as Alzheimer's disease or Parkinson's disease.
  Medline CASGoogle Scholar
• 97. Hollander D, Kaunitz JD. The “leaky gut”: tight junctions but loose associations? Dig. Dis. Sci. 65(5), 1277–1287 (2020).
  MedlineGoogle Scholar
• 98. Nagpal R, Mainali R, Ahmadi S et al. Gut microbiome and aging: physiological and mechanistic insights. Nutr. Healthy Aging 4(4), 267–285 (2018).
  MedlineGoogle Scholar
• 99. Qian Y, Yang X, Xu S et al. Detection of microbial 16S rRNA gene in the blood of patients with Parkinson's disease. Front. Aging Neurosci. 10, 156 (2018).
  MedlineGoogle Scholar
• 100. Forsyth CB, Shannon KM, Kordower JH et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLOS ONE 6(12), e28032 (2011).
  Medline CASGoogle Scholar
• 101. Park A-M, Tsunoda I. Helicobacter pylori infection in the stomach induces neuroinflammation: the potential roles of bacterial outer membrane vesicles in an animal model of Alzheimer's disease. Inflamm. Regen. 42(1), 39 (2022).
  Medline CASGoogle Scholar
• 102. Wang S, Prajapati SK, Mishra SP, Jain S, Yadav H. Protection of cognitive decline and Alzheimer's disease progression by a human origin-probiotic biotherapy. Alzheimers Dement. 18, e066137 (2022).
  Google Scholar
• 103. Li H, Liu C-C, Zheng H, Huang TY. Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease–conformist, nonconformist, and realistic prospects for AD pathogenesis. Transl. Neurodegener. 7, 1–16 (2018).
  MedlineGoogle Scholar
• 104. Shukla PK, Delotterie DF, Xiao J et al. Alterations in the gut–microbial–inflammasome–brain axis in a mouse model of Alzheimer's disease. Cells 10(4), 779 (2021). • Proposes a model wherein modulating the gut microbiota and targeting gut–microbial–inflammasome components represents a promising strategy for preventing or combating Alzheimer's disease-related neurological disorders in genetically susceptible individuals.
  Medline CASGoogle Scholar
• 105. Kaya-Tilki E, Dikmen M. Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: a novel model. PLOS ONE 16(11), e0260633 (2021).
  Medline CASGoogle Scholar
• 106. Ahmadi S, Wang S, Nagpal R et al. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis. JCI Insight 5(9), e132055 (2020). •• Interesting study showing a human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation by increasing the levels of epigenetic modifiers (butyrateand propionate) and hence improves tight junctions.
  MedlineGoogle Scholar
• 107. Ren M, Li H, Fu Z, Li Q. Centenarian-sourced lactobacillus casei combined with dietary fiber complex ameliorates brain and gut function in aged mice. Nutrients 14(2), 324 (2022).
  Medline CASGoogle Scholar
• 108. Zhao X, Kong M, Wang Y et al. Nicotinamide mononucleotide improves the Alzheimer's disease by regulating intestinal microbiota. Biochem. Biophys. Res. Commun. 670, 27–35 (2023).
  Medline CASGoogle Scholar
• 109. Unger MM, Spiegel J, Dillmann K-U et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016). • Demonstrating the importance of gut microbiota and their metabolites as epigenetic modifiers in the quality of life, health and prevention of Parkinson's disease.
  MedlineGoogle Scholar
• 110. Vogt NM, Romano KA, Darst BF et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimer's Res. Ther. 10, 1–8 (2018).
  MedlineGoogle Scholar
• 111. Choudhury SP, Bano S, Sen S et al. Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease. NPJ Parkinson's Dis. 8(1), 66 (2022).
  MedlineGoogle Scholar
• 112. Sampson TR, Debelius JW, Thron T et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167(6), 1469–1480. e1412 (2016).
  Medline CASGoogle Scholar
• 113. Guo X, Tang P, Hou C et al. Integrated microbiome and host transcriptome profiles link Parkinson's disease to Blautia genus: evidence from feces, blood, and brain. Front. Microbiol. 13, 875101 (2022).
  MedlineGoogle Scholar
• 114. Ferreiro AL, Choi J, Ryou J et al. Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Sci. Transl. Med. 15(700), eabo2984 (2023).
  Medline CASGoogle Scholar
• 115. Kundu P, Torres ERS, Stagaman K et al. Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in App NL-GF, App NL-F, and wild type mice. Sci. Rep. 11(1), 4678 (2021).
  Medline CASGoogle Scholar
• 116. Blacher E, Levy M, Tatirovsky E, Elinav E. Microbiome-modulated metabolites at the interface of host immunity. J. Immunol. 198(2), 572–580 (2017).
  Medline CASGoogle Scholar
• 117. Chen S-J, Chen C-C, Liao H-Y et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology 98(8), e848–e858 (2022). • A relatively large human study showing that plasma and fecal short-chain fatty acids (such as butyrate) levels are linked to disease severity in patients with Parkinson's disease.
  Medline CASGoogle Scholar
• 118. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota–gut–brain communication. Nat. Rev. Gastroenterol. Hepatol. 16(8), 461–478 (2019).
  MedlineGoogle Scholar
• 119. Zhang L, Wang Y, Xiayu X et al. Altered gut microbiota in a mouse model of Alzheimer's disease. J. Alzheimer's Dis. 60(4), 1241–1257 (2017).
  Medline CASGoogle Scholar
• 120. Marizzoni M, Cattaneo A, Mirabelli P et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease. J. Alzheimer's Dis. 78(2), 683–697 (2020).
  Medline CASGoogle Scholar
• 121. Xu Y, Wei S, Zhu L et al. Low expression of the intestinal metabolite butyric acid and the corresponding memory pattern regulate HDAC4 to promote apoptosis in rat hippocampal neurons. Ecotoxicol. Environ. Saf. 253, 114660 (2023).
  Medline CASGoogle Scholar
• 122. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 31(9), 2723–2732 (2011).
  Medline CASGoogle Scholar
• 123. Xie A, Ensink E, Li P et al. Bacterial butyrate in Parkinson's disease is linked to epigenetic changes and depressive symptoms. Mov. Disord. 37(8), 1644–1653 (2022).
  Medline CASGoogle Scholar
• 124. Sun Y, Zhang H, Zhang X et al. Promotion of astrocyte–neuron glutamate–glutamine shuttle by SCFA contributes to the alleviation of Alzheimer's disease. Redox. Biol. 62, 102690 (2023).
  Medline CASGoogle Scholar
• 125. Avagliano C, Coretti L, Lama A et al. Dual-hit model of Parkinson's disease: impact of dysbiosis on 6-Hydroxydopamine-insulted mice – neuroprotective and anti-inflammatory effects of butyrate. Int. J. Mol. Sci. 23(12), 6367 (2022).
  Medline CASGoogle Scholar
• 126. Chen G, Ran X, Li B et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine 30, 317–325 (2018).
  Medline CASGoogle Scholar
• 127. Getachew B, Csoka AB, Bhatti A, Copeland RL, Tizabi Y. Butyrate protects against salsolinol-induced toxicity in SH-SY5Y cells: implication for Parkinson's disease. Neurotox. Res. 38, 596–602 (2020).
  Medline CASGoogle Scholar
• 128. Fernando W, Martins IJ, Morici M et al. Sodium butyrate reduces brain amyloid-β levels and improves cognitive memory performance in an Alzheimer's disease transgenic mouse model at an early disease stage. J. Alzheimer's Dis. 74(1), 91–99 (2020).
  Medline CASGoogle Scholar
• 129. Bayazid AB, Jeong YH, Jeong SA, Lim BO. Sodium butyrate alleviates potential Alzheimer's disease in vitro by suppressing Aβ and tau activation and ameliorates Aβ-induced toxicity. Food Agric. Immunol. 34(1), 2234100 (2023).
  Google Scholar
• 130. Jiang Y, Li K, Li X, Xu L, Yang Z. Sodium butyrate ameliorates the impairment of synaptic plasticity by inhibiting the neuroinflammation in 5XFAD mice. Chem. Biol. Interact. 341, 109452 (2021).
  Medline CASGoogle Scholar
• 131. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimer's Dis. 26(1), 187–197 (2011).
  Medline CASGoogle Scholar
• 132. Wang C, Zheng D, Weng F, Jin Y, He L. Sodium butyrate ameliorates the cognitive impairment of Alzheimer's disease by regulating the metabolism of astrocytes. Psychopharmacology (Berl.) 239,215–227 (2022).
  Medline CASGoogle Scholar
• 133. Kilgore M, Miller CA, Fass DM et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35(4), 870–880 (2010).
  Medline CASGoogle Scholar
• 134. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease. Neurosci. Lett. 475(2), 64–68 (2010).
  Medline CASGoogle Scholar
• 135. Yuan B, Liu M, Gong Y et al. Sodium butyrate exerts antioxidant stress effects and attenuates Aβ25-35-induced cytotoxicity in PC12 cells. Arch. Biochem. Biophys. 731, 109448 (2022).
  Medline CASGoogle Scholar
• 136. Sun J, Yuan B, Wu Y et al. Sodium butyrate protects N2a cells against Aβ toxicity in vitro. Mediators Inflamm. 2020, 7605160 (2020).
  MedlineGoogle Scholar
• 137. Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer's disease-type beta-amyloid neuropathological mechanisms. Expert Rev. Neurother. 18(1), 83–90 (2018).
  Medline CASGoogle Scholar
• 138. Long ZM, Zhao L, Jiang R et al. Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase kinase-3β signaling pathway in an Alzheimer's disease model. CNS Neurosci. Ther. 21(11), 887–897 (2015).
  Medline CASGoogle Scholar
• 139. Noh H, Seo H. Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience 266, 255–265 (2014).
  Medline CASGoogle Scholar
• 140. Sorial ME, El Sayed NSED. Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system. Naunyn. Schmiedebergs Arch. Pharmacol. 390, 581–593 (2017).
  Medline CASGoogle Scholar
• 141. Xuan A-G, Pan X-B, Wei P et al. Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer's disease. Mol. Neurobiol. 51, 300–312 (2015).
  Medline CASGoogle Scholar
• 142. Lang W, Li X, Wang Y et al. Sodium propionate improves cognitive and memory function in mouse models of Alzheimer's disease. Neurosci. Lett. 791, 136887 (2022).
  Medline CASGoogle Scholar
• 143. Sharma S, Taliyan R, Singh S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 291, 306–314 (2015).
  Medline CASGoogle Scholar
• 144. Guo T-T, Zhang Z, Sun Y et al. Neuroprotective effects of sodium butyrate by restoring gut microbiota and inhibiting TLR4 signaling in mice with MPTP-induced Parkinson's disease. Nutrients 15(4), 930 (2023).
  Medline CASGoogle Scholar
• 145. Zhang Y, Xu S, Qian Y et al. Sodium butyrate attenuates rotenone-induced toxicity by activation of autophagy through epigenetically regulating PGC-1α expression in PC12 cells. Brain Res. 1776, 147749 (2022).
  Medline CASGoogle Scholar
• 146. Kakoty V, Kc S, Dubey SK, Yang C-H, Taliyan R. Neuroprotective effects of trehalose and sodium butyrate on preformed fibrillar form of α-synuclein-induced rat model of Parkinson's disease. ACS Chem. Neurosci. 12(14), 2643–2660 (2021).
  Medline CASGoogle Scholar
• 147. Rane P, Shields J, Heffernan M, Guo Y, Akbarian S, King JA. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62(7), 2409–2412 (2012).
  Medline CASGoogle Scholar
• 148. Laurent RS, O'brien LM, Ahmad S. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 246, 382–390 (2013).
  MedlineGoogle Scholar
• 149. Paiva I, Pinho R, Pavlou MA et al. Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. Hum. Mol. Genet. 26(12), 2231–2246 (2017).
  Medline CASGoogle Scholar
• 150. Liu J, Wang F, Liu S et al. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J. Neurol. Sci. 381, 176–181 (2017).
  Medline CASGoogle Scholar
• 151. Kakoty V, Kc S, Yang C-H, Dubey SK, Taliyan R. Exploring the epigenetic regulated modulation of fibroblast growth factor 21 involvement in high-fat diet associated parkinson's disease in rats. ACS Chem. Neurosci. 14(4), 725–740 (2023).
  Medline CASGoogle Scholar
• 152. Zhang Y, Xu S, Qian Y et al. Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson's disease by regulating gut microbiota. Front. Aging Neurosci. 15, 1099018 (2023).
  Medline CASGoogle Scholar
• 153. Hou Y, Li X, Liu C et al. Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease. Exp. Gerontol. 150, 111376 (2021).
  Medline CASGoogle Scholar
• 154. Dilmore AH, Martino C, Neth BJ et al. Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease. Alzheimers. Dement. 19(11), 4805–4816 (2023).
  Medline CASGoogle Scholar
• 155. Ma D, Wang AC, Parikh I et al. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci. Rep. 8(1), 6670 (2018).
  MedlineGoogle Scholar
• 156. Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean–ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine 47, 529–542 (2019).
  MedlineGoogle Scholar
• 157. Zhu Y, Tang X, Cheng Z, Dong Q, Ruan G. The anti-inflammatory effect of preventive intervention with ketogenic diet mediated by the histone acetylation of mGluR5 promotor region in rat Parkinson's disease model: a dual-tracer PET study. Parkinsons Dis. 2022, 3506213 (2022).
  MedlineGoogle Scholar
• 158. Cheng B, Yang X, An L, Gao B, Liu X, Liu S. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease. Brain Res. 1286, 25–31 (2009).
  Medline CASGoogle Scholar
• 159. Hernandez AR, Kemp KM, Burke SN, Buford TW, Carter CS. Influence of aging, macronutrient composition and time-restricted feeding on the Fischer344 x brown norway rat gut microbiota. Nutrients 14(9), 1758 (2022).
  Medline CASGoogle Scholar
• 160. Whittaker DS, Akhmetova L, Carlin D et al. Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer's disease. Cell Metab. 35(10), 1704–1721.e6 (2023). •• An interesting study suggesting that dietary programming, such as time-restricted feeding, may serve as effective strategies for enhancing memory in individuals with Alzheimer's disease.
  Medline CASGoogle Scholar
• 161. Zhou Z-L, Jia X-B, Sun M-F et al. Neuroprotection of fasting mimicking diet on MPTP-induced Parkinson's disease mice via gut microbiota and metabolites. Neurotherapeutics 16, 741–760 (2019).
  Medline CASGoogle Scholar
• 162. Hsieh T-H, Kuo C-W, Hsieh K-H et al. Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease. Brain Sci. 10(4), 206 (2020).
  Medline CASGoogle Scholar
• 163. Asl ZR, Sepehri G, Salami M. Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. Behav. Brain Res. 376, 112183 (2019).
  MedlineGoogle Scholar
• 164. Srivastav S, Neupane S, Bhurtel S et al. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. J. Nutr. Biochem. 69, 73–86 (2019).
  Medline CASGoogle Scholar
• 165. Zhang Y, Shen Y, Liufu N et al. Transmission of Alzheimer's disease-associated microbiota dysbiosis and its impact on cognitive function: evidence from mouse models and human patients. Mol. Psychiatry DOI doi: 10.1038/s41380-023-02216-7 (2023).
  Google Scholar
• 166. Li T, Chu C, Yu L et al. Neuroprotective effects of Bifidobacterium breve CCFM1067 in MPTP-induced mouse models of Parkinson's disease. Nutrients 14(21), 4678 (2022).
  Medline CASGoogle Scholar
• 167. Ghyselinck J, Verstrepen L, Moens F et al. Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. Int. J. Pharm: X 3, 100087 (2021).
  Medline CASGoogle Scholar
• 168. Tsao S-P, Nurrahma BA, Kumar R et al. Probiotic enhancement of antioxidant capacity and alterations of gut microbiota composition in 6-hydroxydopamin-induced parkinson's disease rats. Antioxidants 10(11), 1823 (2021).
  Medline CASGoogle Scholar
• 169. Sancandi M, De Caro C, Cypaite N et al. Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson's disease model. Front. Aging Neurosci. 14, 1525 (2023).
  Google Scholar
• 170. Kaur H, Golovko S, Golovko MY, Singh S, Darland DC, Combs CK. Effects of probiotic supplementation on short chain fatty acids in the App NL-GF mouse model of Alzheimer's disease. J. Alzheimer's Dis. 76(3), 1083–1102 (2020).
  Medline CASGoogle Scholar
• 171. Sun J, Xu J, Yang B et al. Effect of Clostridium butyricum against microglia-mediated neuroinflammation in Alzheimer's disease via regulating gut microbiota and metabolites butyrate. Mol. Nutr. Food Res. 64(2), 1900636 (2020).
  CASGoogle Scholar
• 172. Yen C-H, Wang C-H, Wu W-T, Chen H-L. Fructo-oligosaccharide improved brain β-amyloid, β-secretase, cognitive function, and plasma antioxidant levels in D-galactose-treated Balb/cJ mice. Nutr. Neurosci. 20(4), 228–237 (2017).
  Medline CASGoogle Scholar
• 173. Sun J, Liu S, Ling Z et al. Fructooligosaccharides ameliorating cognitive deficits and neurodegeneration in APP/PS1 transgenic mice through modulating gut microbiota. J. Agric. Food Chem. 67(10), 3006–3017 (2019).
  Medline CASGoogle Scholar
• 174. Wu S, Zhang J, Jiang C, Wang S, Que R, An L. Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease. Food Funct. 11(7), 6565–6572 (2020).
  Medline CASGoogle Scholar
• 175. Wang N, Feng B-N, Hu B, Cheng Y-L, Guo Y-H, Qian H. Neuroprotection of chicoric acid in a mouse model of Parkinson's disease involves gut microbiota and TLR4 signaling pathway. Food Funct. 13(4), 2019–2032 (2022).
  Medline CASGoogle Scholar
• 176. Zhang S, Wei D, Lv S et al. Scutellarin modulates the microbiota–gut–brain axis and improves cognitive impairment in APP/PS1 mice. J. Alzheimer's Dis. 89(3), 955–975 (2022).
  Medline CASGoogle Scholar
• 177. Pyo IS, Yun S, Yoon YE, Choi J-W, Lee S-J. Mechanisms of aging and the preventive effects of resveratrol on age-related diseases. Molecules 25(20), 4649 (2020).
  Medline CASGoogle Scholar
• 178. Grinan-Ferre C, Bellver-Sanchis A, Izquierdo V et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: from antioxidant to epigenetic therapy. Ageing Res. Rev. 67, 101271 (2021).
  Medline CASGoogle Scholar
• 179. Tao J, An Y, Xu L et al. The protective role of microbiota in the prevention of MPTP/P-induced Parkinson's disease by resveratrol. Food Funct. 14(10), 4647–4661 (2023).
  Medline CASGoogle Scholar
• 180. Zhang W, Guo Y, Cheng Y, Yao W, Qian H. Neuroprotective effects of polysaccharide from Sparassis crispa on Alzheimer's disease-like mice: involvement of microbiota–gut–brain axis. Int. J. Biol. Macromol. 225, 974–986 (2023).
  Medline CASGoogle Scholar
• 181. Behera J, Kelly KE, Tyagi N. Altered non-coding RNA-histone acetylation regulatory circuit is associated with cognitive impairment via gut dysbiosis in aging mice. FASEB J. 33(S1), 714.713 (2019).
  Google Scholar
• 182. Abdolmaleky HM, Zhou J-R. Underlying mechanisms of brain aging and neurodegenerative diseases as potential targets for preventive or therapeutic strategies using phytochemicals. Nutrients 15(15), 3456 (2023).
  Medline CASGoogle Scholar
• 183. Bordoni L, Gabbianelli R, Fedeli D et al. Positive effect of an electrolyzed reduced water on gut permeability, fecal microbiota and liver in an animal model of Parkinson's disease. PLOS ONE 14(10), e0223238 (2019).
  Medline CASGoogle Scholar
• 184. Cuervo-Zanatta D, Syeda T, Sánchez-Valle V et al. Dietary fiber modulates the release of gut bacterial products preventing cognitive decline in an Alzheimer's mouse model. Cell. Mol. Neurobiol. 43(4), 1595–1618 (2023).
  Medline CASGoogle Scholar
• 185. Koutzoumis DN, Vergara M, Pino J et al. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease. Exp. Neurol. 325, 113159 (2020).
  Medline CASGoogle Scholar
• 186. Bakker GJ, Nieuwdorp M. Fecal microbiota transplantation: therapeutic potential for a multitude of diseases beyond Clostridium difficile. Microbiol. Spectr. 5(4), doi: 10.1128/microbiolspec. bad-0008-2017 (2017).
  MedlineGoogle Scholar
• 187. Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 44, 716–729 (2019).
  MedlineGoogle Scholar
• 188. Zhong Z, Chen W, Gao H et al. Fecal microbiota transplantation exerts a protective role in MPTP-induced Parkinson's disease via the TLR4/PI3K/AKT/NF-κB pathway stimulated by α-synuclein. Neurochem. Res. 46, 3050–3058 (2021).
  Medline CASGoogle Scholar
• 189. Sun J, Xu J, Ling Y et al. Fecal microbiota transplantation alleviated Alzheimer's disease-like pathogenesis in APP/PS1 transgenic mice. Transl. Psychiatry 9(1), 189 (2019).
  MedlineGoogle Scholar